Tony Keating, Ph.D.
Chief Executive Officer and Managing Director
Tony has over 10 years’ experience in commercialising technology. Tony created the initial business strategy for ResApp and has led the commercialization of ResApp’s technology to date. Previously, Tony was Director, Commercial Engagement at UniQuest Pty Ltd, one of the global leaders in commercialisation of university technology. While at UniQuest, Tony held roles as interim Chief Executive Officer and Non-Executive Director for a number of privately-held, venture-capital funded start-up companies. Prior to joining UniQuest Tony held business development and engineering management roles at Exa Corporation, a US-based software company that is now listed on the NASDAQ.
Tony holds a Bachelor of Engineering, a Master of Engineering Science and a Doctor of Philosophy (Mechanical Engineering) from The University of Queensland. Tony also has an Executive Certificate of Management and Leadership from the MIT Sloan School of Management, and is a Graduate Member of the Australian Institute of Company Directors.
Udantha Abeyratne, Ph.D.
Scientific Founder and Consultant
Udantha is a biomedical engineer with over 25 years experience in medical instrumentation and signal processing. He is the lead inventor of ResApp’s founding patented technology and is the author of numerous publications on the use of digital signal processing and machine learning for the diagnosis of sleep apnea and respiratory disease. In 2016, Engineers Australia named Udantha as one of Australia’s Most Innovative Engineers.
Udantha holds a Bachelor of Engineering from the University of Peradeniya, a Masters of Engineering from Tokushima University and a Doctor of Philosophy (Biomedical Engineering) from Drexel University. He also has a Graduate Certificate in Paediatric Sleep Science from the University of Western Australia. Udantha is an Associate Professor in the School of Information Technology and Electrical Engineering at the University of Queensland.
Vice President, Corporate Affairs
Brian is a marketing and investor relations professional with over 10 years’ experience in the biotechnology industry. Mr Leedman was co-founder of ResApp Diagnostics Pty Ltd which was acquired by Narhex Life Sciences Ltd to form ResApp Health. Prior to ResApp, Brian co-founded Oncosil Medical Limited and Biolife Science Limited (acquired by Imugene Limited). Brian previously served for 10 years as Vice President, Investor Relations for pSivida Corp which is listed on the ASX and NASDAQ.
Brian holds a Bachelor of Economics and a Masters of Business Administration from the University of Western Australia.
Kay Taylor, Ph.D.
Vice President, Emerging Markets
Kay is a life sciences commercialisation specialist with over 15 years experience in the life sciences sector. She joined ResApp Health from UniQuest Pty Ltd where she was most recently the Director of Startup and License Portfolio Asset Management. In this role she was responsible for driving the short and long term objectives for the life sciences portfolio of over 50 startups and 100 active licenses. Prior to UniQuest, Kay worked for two multinational life sciences companies in technical sales roles, providing support to customers across the Asia-Pacific region.
Kay holds a Bachelor of Applied Science and a Doctor of Philosophy from QUT both in Molecular Biotechnology. She is also a Graduate Member of the Australian Institute of Company Directors.
Vice President, Technology
Rob has over 20 years of experience in software design and development and has worked in iOS and Mac development for more than 10 years. Rob has worked in diverse business areas, he most recently built apps for some of the world’s leading music labels, brands and companies and he was responsible for product design and development of a digital publishing platform that powers many of the top ranking magazines on the Apple App Store.
Director, Sales and Marketing (Europe)
Jamie has over 20 years of experience in the medical device industry, building successful sales infrastructure and driving growth on a global scale. Prior to joining ResApp, Jamie was International Sales Director at MolecuLight, whose lead product is a CE Marked handheld point-of-care wound-imaging device. Prior to MolecuLight, the majority of Jamie’s career was spent at Olympus Medical where he held a number of senior sales and marketing roles in the UK, Middle East and Africa.
ResApp Health Limited
ABN 51 094 468 318
Level 12, 100 Creek St, Brisbane, QLD 4000
© 2021 ResApp Health Limited. All rights reserved. US Patent No. 10,098,569, Australian Patent No. 2013239327, Japanese Patent No. 6,435,257, South Korean Patent No. 1020812410000 and Patents Pending. ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States and other countries. ResAppDx is not available for sale in the United States.